Forbius
Edit

Forbius

https://forbius.com/#about
Last activity: 05.06.2020
Tags:BioTechBodyDesignDevelopmentEngineeringGrowthInformationMedtechPlatform
About Forbius: Targeting EGFR and TGF-β Pathways in Cancer and Fibrosis Forbius is a clinical stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. We use our strength in biological understanding and diverse protein engineering technologies to design superior inhibitors of validated pathways. We have particularly deep expertise in targeting the transforming growth factor-beta (TGF-β) and epidermal growth factor receptor (EGFR) pathways. For both of these pathways, there is a significant body of evidence validating their role as drivers of multiple life-threatening conditions, including cancer and fibrosis. However, in the case of the EGFR pathway, the majority of patients do not benefit from currently marketed EGFR inhibitors; in the case of the TGF-β pathway, no agent targeting this pathway has yet been approved. By using multiple complementary platform technologies, Forbius’ team overcame barriers that prevented the development of effective therapeutics targeting these pathways. For more information, please visit www.forbius.com.
Location: United States, Texas, Austin
Member count: 11-50
Total raised: $18.8M
Founded date: 2011

Investors 2

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
24.08.2018Grant$18.8M-lumiravent...

Mentions in press and media 13

DateTitleDescriptionSource
05.06.2020Forbius Reported Safety and Initial Anti-Fibrotic Effects of...Austin, TX, and Montreal, QC (Jun. 5, 2020) – Forbius, a clinical-stage protein engineering company ...lumiravent...
08.11.2019Forbius Completes Phase 1 Oncology Dose Escalation with AVID...Austin, TX, and Montreal, QC (Nov. 8, 2019) – Forbius, a clinical-stage protein engineering company ...lumiravent...
15.10.2019Forbius Completes Phase 1a Solid Tumor Trial Enrollment &...Austin, TX, and Montreal, QC – Forbius, a clinical-stage protein engineering company that develops b...lumiravent...
29.05.2019Health Canada Clears Forbius’ AVID100 to Commence Phase 2 Cl...Austin, TX and Montreal, QC (May 28, 2019) – Forbius, a clinical-stage company that develops novel b...lumiravent...
29.04.2019Forbius’ AVID200, a Novel TGF-beta 1 & 3 Inhibitor, Clea...Austin, TX, and Montreal, QC (Apr. 29, 2019) – Forbius, a clinical-stage company that develops novel...lumiravent...
24.04.2019Forbius: First Patient Dosed in a Phase 1b Myelofibrosis Tri...Austin, TX and Montreal, QC (Apr. 24, 2019) – Forbius, a clinical-stage company that develops novel ...lumiravent...
22.04.2019Forbius Announces First Patient Dosed in Phase 2a Triple Neg...Austin, TX, and Montreal, QC (Apr. 22, 2019) – Forbius, a clinical-stage company that develops novel...lumiravent...
07.03.2019Forbius Announces First Patient Dosed in Phase 2a Squamous C...Austin, TX, and Montreal, QC (Mar. 7, 2019) – Forbius, a clinical-stage company that develops novel ...lumiravent...
04.03.2019Forbius Announces the First Patient Dosed in a Phase 1b Diff...Austin, TX, and Montreal, QC (Mar. 4, 2019) – Forbius, a clinical-stage company that develops biolog...lumiravent...
14.02.2019Forbius Collaborates with the Icahn School of Medicine at Mo...Austin, TX and Montreal, QC (Feb. 14, 2019) – Forbius, a clinical-stage company that develops biolog...lumiravent...
Show more